Pancreatic Cancer Research

ResearcherHiroshima UniversityActive in the last 2 years

Tatsuaki Sumiyoshi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8459-3699; OpenAlex author ID A5075368980. Sources: OpenAlex.

Their work

Papers
28
Trials
0
Grants
0
Labs led
0
Collaborators
33
Papers, trials and grants by year

2015: 2 papers · 2016: none · 2017: 1 paper · 2018: 1 paper · 2019: none · 2020: 1 paper · 2021: 5 papers · 2022: 6 papers · 2023: 4 papers · 2024: 3 papers · 2025: 1 paper · 2026: 4 papers

Papers 28

  1. Independent Prognostic Value of Natural Tooth Count Versus Posterior Teeth Occlusion in Resected Pancreatic Cancer. Co-author DOI 10.1002/jhbp.70113↗
  2. Long-term disease control of GP2-NTRK1 fusion-positive pancreatic adenocarcinoma with liver metastases using sequential tyrosine receptor kinase inhibitors. Co-author DOI 10.1007/s12328-026-02388-z↗
  3. Prognostic Impact of the Combined Use of CA19-9 and DUPAN-2 in Initially Unresectable Locally Advanced Pancreatic Adenocarcinoma. Co-author DOI 10.1245/s10434-026-20710-4↗
  4. ASO Author Reflections: Assessment of Malignant Potential in Initially Unresectable Locally Advanced Pancreatic Ductal Adenocarcinoma by Combining CA19-9 and D… Co-author DOI 10.1245/s10434-026-20761-7↗
  5. Survival benefit of adjuvant therapy completion with early initiation for patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ags3.12898↗
  6. Long-term outcomes of neoadjuvant gemcitabine, nab-paclitaxel, and S1 (GAS) in borderline resectable pancreatic cancer with arterial contact: Results from a ph… Co-author DOI 10.1002/jhbp.1412↗
  7. Clinical Utility of the Combined Use of CA19-9 and DUPAN-2 in Pancreatic Adenocarcinoma. Co-author DOI 10.1245/s10434-024-15221-z↗
  8. ASO Author Reflections: Accurate Evaluation of Malignant Potential in Pancreatic Ductal Adenocarcinoma Using DUPAN-2 Level. Co-author DOI 10.1245/s10434-024-15272-2↗
  9. Surgical resection for liver recurrence after curative resection of pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00423-023-03009-w↗
  10. Prognostic factor in patient with recurrent pancreatic adenocarcinoma. Co-author DOI 10.1007/s00423-023-03073-2↗
  11. Pathologic complete response following FOLFIRINOX and olaparib treatment for hepatic metastasized pancreatic ductal adenocarcinoma with a germline BRCA mutatio… Co-author DOI 10.1007/s12328-022-01741-2↗
  12. Increased plasma miR-370-3p expression in poor-outcome patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2023.10.019↗
  13. Prognosis following an extended duration of adjuvant gemcitabine plus S-1 chemotherapy in patients with pancreatic ductal adenocarcinoma: Analysis using invers… Co-author DOI 10.1002/jhbp.1151↗
  14. Neoadjuvant therapy contributes to nodal downstaging of pancreatic cancer. Co-author DOI 10.1007/s00423-021-02339-x↗
  15. Long-term survival after distal pancreatectomy with celiac axis resection and hepatic artery reconstruction in the setting of locally advanced unresectable pan… Co-author DOI 10.1007/s12328-022-01621-9↗
  16. Increased clostridium difficile infection in the era of preoperative chemotherapy for pancreatic cancer. Co-author DOI 10.1016/j.pan.2021.12.009↗
  17. Impact of disintegrin and metalloproteinase domain-containing protein 12 on pancreatic ductal adenocarcinoma treated with surgical resection and perioperative … Co-author DOI 10.1016/j.pan.2022.03.018↗
  18. Preoperative risk factors for positivity of peritoneal lavage cytology in patients with pancreatic ductal adenocarcinoma in the era of neoadjuvant therapy. Co-author DOI 10.1016/j.pan.2022.04.004↗
  19. Prognostic significance of dissecting the nerve plexus around the common hepatic artery in pancreatic cancer. Co-author DOI 10.1007/s00423-020-02025-4↗
  20. Prognostic Value of Peritoneal Lavage Cytology in Patients with Pancreatic Ductal Adenocarcinoma Stratified by the Resectability Status. Co-author DOI 10.1007/s11605-021-04978-3↗
  21. A phase II study of gemcitabine/nab-paclitaxel/S-1 combination neoadjuvant chemotherapy for patients with borderline resectable pancreatic cancer with arterial… Co-author DOI 10.1016/j.ejca.2021.10.012↗
  22. Preoperative risk factors for para-aortic lymph node positivity in pancreatic cancer. Co-author DOI 10.1016/j.pan.2021.01.022↗
  23. Identification of Preoperative Risk Factors for Poor Survival in Patients with Resectable Pancreatic Cancer Treated with Upfront Surgery. Co-author DOI 10.1159/000520064↗
  24. Clinical characteristics of initial recurrence in lung after surgical resection for pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2020.08.019↗
  25. A Novel Physiobiological Parameter-Based Grading System for Resectable Pancreatic Cancer. Co-author DOI 10.1245/s10434-018-6485-7↗
  26. Clinical effects of chemoradiotherapy in pursuit of optimal treatment of locally advanced unresectable pancreatic cancer. Co-author DOI 10.1259/bjr.20170165↗
  27. Reconsideration about the aggressive surgery for resectable pancreatic cancer: a focus on real pathological portosplenomesenteric venous invasion. Co-author DOI 10.1007/s00423-015-1305-z↗
  28. Completion pancreatectomy for recurrent pancreatic cancer in the remnant pancreas: report of six cases and a review of the literature. Co-author DOI 10.1007/s00423-015-1355-2↗

Closest collaborators

The 25 strongest of 33 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kenichiro Uemura · 24 shared papers, 2020–2026 · strength 4.99
  2. Kenjiro Okada · 21 shared papers, 2020–2026 · strength 3.61
  3. Yoshiaki Murakami · 18 shared papers, 2020–2026 · strength 3.09
  4. Shin’ya Takahashi · 19 shared papers, 2020–2025 · strength 3.05
  5. Hiroyuki Otsuka · 15 shared papers, 2020–2023 · strength 2.20
  6. Naru Kondo · 13 shared papers, 2020–2024 · strength 1.90
  7. Ryuta Shintakuya · 8 shared papers, 2023–2026 · strength 1.75
  8. Yasutaka Ishii · 8 shared papers, 2021–2026 · strength 1.49
  9. Takumi Harada · 5 shared papers, 2023–2026 · strength 1.11
  10. Kenta Baba · 5 shared papers, 2023–2026 · strength 1.10
  11. Takeshi Sudo · 3 shared papers, 2021–2026 · strength 0.63
  12. Shinya Takahashi · 2 shared papers, 2026 · strength 0.59
  13. Sho Tazuma · 2 shared papers, 2026 · strength 0.55
  14. Shiro Oka · 2 shared papers, 2025–2026 · strength 0.51
  15. Tomofumi Tsuboi · 3 shared papers, 2021–2023 · strength 0.43
  16. Yoshiyuki Shibata · 2 shared papers, 2022–2023 · strength 0.33
  17. Kaoru Seo · 1 shared paper, 2026 · strength 0.30
  18. Takuya Sakoda · 2 shared papers, 2021–2022 · strength 0.29
  19. Yosuke Shimizu · 1 shared paper, 2026 · strength 0.29
  20. Hirotaka Tashiro · 1 shared paper, 2026 · strength 0.29
  21. Shinya Takahashi · 1 shared paper, 2026 · strength 0.26
  22. Juri Ikemoto · 1 shared paper, 2026 · strength 0.26
  23. Masaru Furukawa · 1 shared paper, 2026 · strength 0.26
  24. Jun Iwata · 4 shared papers, 2015–2018 · strength 0.24
  25. Yasuo Shima · 4 shared papers, 2015–2018 · strength 0.24

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.